Veru (VERU) to Release Quarterly Earnings on Thursday

Veru (NASDAQ:VERU) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $3.02 million for the quarter.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veru Trading Up 17.3 %

NASDAQ VERU opened at $0.61 on Thursday. The company has a market cap of $89.47 million, a price-to-earnings ratio of -2.18 and a beta of -0.53. Veru has a 1-year low of $0.36 and a 1-year high of $1.92. The company has a 50 day moving average of $0.75 and a 200-day moving average of $0.80.

Analyst Ratings Changes

VERU has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Veru in a research note on Thursday, January 2nd. Oppenheimer reissued an “outperform” rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.